Showing results (1181-1190 of 3,351) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|November 10, 2001
Using health outcomes data to inform decision-making: patient perspectiveE RameckersPharmacoeconomics|January 31, 2002
Onychomycosis: health-related quality of life considerationsJames W Shaw, Vijay N Joish, Stephen Joel CoonsPharmacoeconomics|January 31, 2002
Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomised controlled trialAndreas Maetzel, Vibeke Strand, Peter Tugwell, et al.Pharmacoeconomics|April 4, 2001
Usefulness of US cost-of-illness studies in healthcare decision makingB S Bloom, D J Bruno, D Y Maman, et al.Pharmacoeconomics|March 17, 2001
Enteroviral meningitis. Cost of illness and considerations for the economic evaluation of potential therapiesT V Parasuraman, K Frenia, J RomeroPharmacoeconomics|March 17, 2001
Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST-segment elevation acute coronary syndromes. Estimating the economic implicationsW B Hillegass, A R Newman, D L RacoPharmacoeconomics|March 17, 2001
Dermatan sulfate versus unfractionated heparin for the prevention of venous thromboembolism in patients undergoing surgery for cancer. A cost-effectiveness analysisE Attanasio, P Russo, G Carunchio, et al.Pharmacoeconomics|March 17, 2001
A general model of the effects of sleep medications on the risk and cost of motor vehicle accidents and its application to FranceJ Menzin, K M Lang, P Levy, et al.Pharmacoeconomics|March 17, 2001
Economic analysis of initial HIV treatment. Efavirenz- versus indinavir-containing triple therapyJ J Caro, J A O'Brien, K Migliaccio-Walle, et al.Pharmacoeconomics|January 11, 2001
Health-related quality-of-life measurement in hypertension. A review of randomised controlled drug trialsI Côté, J P Grégoire, J MoisanPageof 336